Request Demo

Last update 08 May 2025

Clobetasol Propionate

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate, Clobetasol Propionate Cream, Clobetasol Propionate Liniment

+ [38]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesHemic and Lymphatic Diseases+ [4]

Active Indication

PainPain, PostoperativePost procedural inflammation+ [17]

Inactive Indication

Chronic large plaque psoriasisDandruffDermatophilosis+ [3]

Originator Organization

Novartis Pharma AG

Active Organization

Primus Pharmaceuticals, Inc.

Guangdong Shunfeng Pharmaceutical Co., Ltd.Formosa Pharmaceuticals, Inc.

+ [10]

Inactive Organization

AFYX Therapeutics AS

Galderma Holding SA

Promius Pharma LLC

+ [2]

License Organization

Apotex, Inc.Formosa Pharmaceuticals, Inc.

Eyenovia, Inc.

+ [12]

Drug Highest PhaseApproved

First Approval Date

Japan (19 Apr 1979),

Eczema

Regulation-

Structure/Sequence

Molecular FormulaC25H32ClFO5

InChIKeyCBGUOGMQLZIXBE-XGQKBEPLSA-N

CAS Registry25122-46-7

116

Clinical Trials associated with Clobetasol Propionate

NCT06504160

/ RecruitingPhase 1/2IIT

Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization.
The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.

Start Date10 Apr 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+2]

NCT06856590

/ RecruitingNot ApplicableIIT

Impact of Zinc Supplementation and Transdermal Clobetasol in the Prophylaxis of Regorafenib-Induced Hand-Foot Skin Reaction: a Prospective Non-Randomized Study

This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib treatment.
HFSR is one of the most common adverse effects of regorafenib, affecting more than 50% of patients, with 10-15% experiencing severe Grade 3 toxicity. Clobetasol, a high-potency corticosteroid, has been shown to significantly reduce the severity of HFSR when used preemptively rather than reactively. Additionally, recent clinical trials indicate that oral zinc supplementation may further reduce the incidence of Grade ≥2 HFSR.
This prospective, non-randomized interventional study will compare three treatment groups:
Oral zinc supplementation + transdermal clobetasol cream Transdermal clobetasol cream alone Oral zinc supplementation alone The study will assess the effectiveness of these treatments using CTCAE grading, the Hand-Foot Syndrome Scale-14, and quality of life measures (FACT-G, fatigue, and anxiety/depression scales). Additionally, the study will evaluate the impact of HFSR on treatment adherence, regorafenib dose modifications, and overall survival.
The study will enroll approximately 120 patients across multiple centers in Türkiye.

Start Date20 Feb 2025

Sponsor / Collaborator

Gazi University

IRCT20200810048352N3

/ RecruitingPhase 1/2IIT

Comparison of anti-inflammatory effect of lotion preparation from hydroalcoholic extract of Dracocephalum kotschyi and clobetasol on patient suffering from eczema.

Start Date21 Dec 2024

Sponsor / Collaborator

Isfahan University of Medical Sciences

100 Clinical Results associated with Clobetasol Propionate

100 Translational Medicine associated with Clobetasol Propionate

100 Patents (Medical) associated with Clobetasol Propionate

3,378

Literatures (Medical) associated with Clobetasol Propionate

01 May 2025·Biochemical and Biophysical Research Communications

Propionate alleviates diabetes-induced cardiac fibrosis in mice via regulating Serpinf1

Article

Author: Lu, Weida ; Li, Kaiwen ; Wang, Yuanyuan ; Zhang, Hongyu ; Ji, Xiaoping ; Yao, Guihua ; Sun, Hui ; Bu, Fangfang ; Zhong, Jingquan

BACKGROUNDDiabetic cardiomyopathy is a severe cardiovascular complication that adversely affects the heart health of diabetic patients. This study aims to investigate the therapeutic effects of propionate on the cardiac fibrosis phenotype in diabetic mice and to elucidate its underlying mechanisms.METHODSA streptozotocin-induced diabetic mouse model was used in the experiments. After successful induction of diabetes, the mice received propionate treatment. Cardiac fibrosis and inflammatory factor levels were assessed using histological analysis and biochemical assays. Furthermore, single-cell RNA sequencing and primary mouse cardiac fibroblast sequencing data were analyzed to explore the potential mechanisms underlying propionate's effects on diabetic cardiac fibrosis. Finally, the molecular mechanism by which propionate reverses diabetes-induced cardiac fibrosis was validated using shRNA knockdown experiments.RESULTSThe results showed that propionate treatment significantly improved cardiac fibrosis in diabetic mice and reduced the levels of inflammatory factors in cardiac tissues. Additionally, propionate upregulated the expression of the Serpinf1 gene, inhibited the abnormal activation of the Wnt signaling pathway, and reduced fibrosis and marker expression levels in high-glucose-induced cardiac fibroblasts.CONCLUSIONSThe main conclusion of this study is that propionate effectively improves the diabetic cardiac fibrosis phenotype in mice, and this therapeutic effect is specific to pathological conditions. The study further identifies Serpinf1 as the molecular target of propionate's action. These findings not only enhance our understanding of the pathophysiological mechanisms of diabetic cardiomyopathy but also provide new strategic insights for diabetes treatment, holding significant clinical application potential.

01 May 2025·Phytomedicine

Angelicin ameliorated ulcerative colitis through activating HDAC1-derived HIF-1α acetylation

Article

Author: Chen, Siyuan ; Zhang, Caijuan ; Xian, Junying ; Zhu, Lin ; Liu, Jianyao ; Liu, Haifan ; Yang, Weipeng ; Wang, Dunfang ; Liu, Bin ; Feng, Xue ; Zuo, Xingbo ; Sun, Jingwei ; Liu, Li

BACKGROUNDUlcerative colitis (UC) is a stubborn disease that occurs globally. SSP-TXYF is a traditional Chinese medicine (TCM) compound, which is widely used in the treatment of UC, but its picking and preparation is complicated. Therefore, this work analyzes the components of SSP-TXYF to find an natural compound that can treat UC, and verifies its efficacy and mechanism, aiming to explore new natural compound with the same efficacy as SSP-TXYF.METHODS AND RESULTSIn this study, we used the quality markers (Q-marker) strategy to analyze the SSP-TXYF. We obtained that angelicin (Ang) is the main active ingredient. Combined with reductive dimethyl labeling and tandem orthogonal proteolysis-activity-based protein profiling (rdTOP-ABPP) and network pharmacology, we found that ERK1/2 and HDAC1 may be the binding proteins. Then, we demonstrated that Ang not only suppresses inflammation in lipopolysaccharide-induced IEC-6 but also effectively inhibits 2,4,6-trinitrobenzenesulfonic acid-induced UC in vivo. Increasing the concentration of propionate and butyrate, activating GPR43 and GPR109A receptors, increasing ERK1/2 activity, promoting Sp1 phosphorylation, thus competitively inhibiting the combination of HIF-1α and HDAC1, and finally increasing the acetylation of HIF-1α is the molecular signaling mechanism for Ang.CONCLUSIONSIn conclusion, Ang can improve the symptoms of UC in rats and activate the GPR/ERK/SP1/HDAC1/HIF-1α pathway in colonic epithelial cells to repair the damaged intestinal mucosal barrier (IMB). The key pharmacodynamic mechanism of Ang is consistent with SSP-TXYF, and it is preliminarily believed that Ang can be used as a new natural medicine for treating UC.

22 Apr 2025·JCI Insight

Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD

Article

Author: Lauschke, Volker M ; Burk, Oliver ; Felder, Thomas K ; Datz, Christian ; Aigner, Elmar ; Paulweber, Bernhard ; Tevini, Julia ; Schwab, Matthias ; Haag, Mathias ; Winter, Stefan ; Kemas, Aurino M ; Eder, Sebastian K ; Feldman, Alexandra ; Liebisch, Gerhard

BACKGROUNDAlterations in circulating metabolites have been described in obese metabolic dysfunction-associated steatotic liver disease (MASLD), but data on lean MASLD are lacking. We investigated serum metabolites, including microbial bile acids and short-chain fatty acids (SCFAs), and their association with lean and obese MASLD.METHODSSerum samples from 204 people of European descent were allocated to groups: lean healthy, lean MASLD, obese healthy, and obese MASLD (n = 47). Liquid chromatography-mass spectrometry-based metabolomics and linear model analysis were performed. MASLD prediction was assessed based on least absolute shrinkage and selection operator regression. Functional effects of altered molecules were verified in organotypic 3D primary human liver cultures.RESULTSLean MASLD was characterized by elevated isobutyrate, methionine sulfoxide, propionate, and phosphatidylcholines. Patients with obese MASLD had increased sarcosine and decreased lysine and asymmetric dimethylarginine. Using metabolites, sex, and BMI, MASLD versus healthy could be predicted with a median AUC of 86.5% and 85.6% in the lean and obese subgroups, respectively. Functional experiments in organotypic 3D primary human liver cultures showed propionate and isobutyrate induced lipid accumulation and altered expression of genes involved in lipid and glucose metabolism.CONCLUSIONLean MASLD is characterized by a distinct metabolite pattern related to amino acid metabolism, lipids, and SCFAs, while metabolic pathways of lipid accumulation are differentially activated by microbial metabolites. We highlight an important role of microbial metabolites in MASLD, with implications for predictive and mechanistic assessment of liver disease across weight categories.FUNDINGRobert Bosch Stiftung, Swedish Research Council (2021-02801, 2023-03015, 2024-03401), ERC Consolidator Grant 3DMASH (101170408), Ruth and Richard Julin Foundation for Gastroenterology (2021-00158), SciLifeLab and Wallenberg National Program for Data-Driven Life Science (WASPDDLS22:006), Novo Nordisk Foundation (NNF23OC0085944, NNF23OC0084420), PMU-FFF (E-18/28/148-FEL).

News (Medical) associated with Clobetasol Propionate

26 Apr 2025

·www.prnewswire.com

Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

TAIPEI, April 25, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Laboratorios Saval ("Saval"), a Chilean-based pharmaceutical company operating in Central and South America, for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative treatment of post-operative inflammation and pain following ocular surgery. Saval, a family-owned pharmaceutical company founded in 1938, boasts its own internal R&D and GMP manufacturing facilities, while holding international strategic partners. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was launched in the United States in September. The licensing agreement includes upfront payment and milestones, with additional considerations throughout the term of the agreement. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain. In a recent US survey of 100 ophthalmic surgeons, rapid resolution of pain (~80% pain-free four days post-surgery) and low incidence of adverse events (<2%) were highlighted as key drivers to prescribing APP13007. APP13007 anticipates having significant potential in Saval's territories, whose ophthalmic corticosteroid market is estimated at almost USD $7.5 million, currently led by treatments with a less convenient dosing regimen (4 to 6 times daily). "We are pleased that Saval has identified APP13007 as a worthy therapy to include in their ophthalmology core business unit. Saval's vast network throughout Latin America will guarantee that patients recovering from ocular surgery will have access to APP13007." said Erick Co, President and CEO of Formosa Pharmaceuticals. "At Saval we are committed to providing patients with affordable and high-quality products in a broad range of therapeutic areas throughout Latin America. Ophthalmology is part of our core and APP13007 will provide physicians and patients with an innovative and valuable addition to the available treatment options. We are pleased to partner with Formosa Pharmaceuticals and look forward to working together for Latin American patients and physicians" said Nicolás Donoso, CEO of Laboratorios Saval. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in safety, delivery, and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit . About Saval Corporation: Laboratorios Saval S.A. is based in Santiago, Chile and currently is present in 14 countries in Central and South America. For more than 85 years, Saval has provided patients and physicians with affordable and high-quality products in multiple therapeutic areas. For more information, please refer to . SOURCE Formosa Pharmaceuticals Inc., WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inDrug Approval

10 Apr 2025

·www.globenewswire.com

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. Eyenovia continues to advance the Optejet UFD through Verification & Validation (V&V) studies to ensure that the device meets the standards around intended use and customer requirements. As of today, the Company has completed the following parameters: Physical requirements such as dimensions and weight, and presence and operation of various light indicatorsUsability requirements identified, including forces required to actuate the device or connect and disconnect the cartridgeDosing performance, with consistency in delivering ophthalmic liquids to within a standard deviation of 1 microliter.Longevity testing demonstrating that the device can operate without failure for the intended life span and with a sufficient safety factor. In particular, tested key components more than 30,000 times, and demonstrated that the device can precisely dispense the ophthalmic solution well beyond 30,000 actuations. Safety testing of the base according to recognized standards, such as IEC 60601, to ensure performance specifications are met. This testing includes, among other things, electromagnetic interference, compatibility, and electrostatic discharge testing. The Optejet UFD has satisfactorily met all requirements. “The user-filled Optejet device is well on its way towards registration,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “The combination of the UFD Optejet with an artificial tear or lens rewetting solution may significantly enhance the user experience while allowing many consumers to obtain twice as many uses from their current eyedrops. We look forward to completing the remaining V&V studies and preparing for a 510(k) submission as early as September of this year.” About Eyenovia, Inc.Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more information, please visit Eyenovia.com. Forward Looking StatementsExcept for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including those relating to the completion of due diligence on and a definitive transaction agreement in conjunction with our strategic processes, the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the risk that any proposed transactions do not proceed; risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.com Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363

20 Mar 2025

·www.globenewswire.com

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a non-binding letter of intent (LOI) contemplating a potential reverse merger transaction with Betaliq, Inc., a clinical stage pharmaceutical company with a therapeutic focus on glaucoma. The proposed merger would create a new ophthalmic company that combines two FDA-approved technologies: Betaliq’s EyeSol® water-free drug delivery technology for use in glaucoma, and Eyenovia’s Optejet topical ophthalmic liquid dispensing platform. The proposed transaction remains subject to completion of mutually satisfactory due diligence, the negotiation and execution of definitive agreements on mutually satisfactory terms, the approval of such definitive documentation by the boards of directors of both Eyenovia and Betaliq, and the completion of necessary financing contingencies. There can be no assurance that any such agreement will be executed or the proposed transaction with Betaliq will be consummated, or as to the timing of the entry of any such agreement or the consummation of such proposed transaction. The proposed transaction assumes a value for Betaliq of approximately $77 million and a value for Eyenovia of approximately $15 million, assuming zero cash (net of liabilities) at merger closing. The exchange ratio is intended to result in Betaliq equity holders owning approximately 83.7% of the combined company, while Eyenovia equity holders would own approximately 16.3% at the closing of the merger, on a fully diluted basis. Betaliq’s EyeSol technology offers increased bioavailability and a drop size of 10 microliters that can be replicated in the Optejet device. The EyeSol technology is currently used and licensed in FDA-approved topical eye care medications, including MEIBO™ (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and VEVYE™ (cyclosporine ophthalmic solution 0.1%, Harrow) Eyenovia’s Optejet dispensing platform, in addition to providing similar benefits to those provided by EyeSol, also may enhance the performance of products by making it easier to use and comply with therapy. Importantly, EyeSol is compatible with the Optejet. Eyenovia continues to advance development of the user-filled Optejet and remains on track to file for U.S. regulatory approval in the fourth quarter of this year. The user-filled Optejet is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. “Following a review of strategic alternatives that we initiated in January, I, along with my fellow Board members, concluded that continuing the negotiation of this potential merger with Betaliq is in the best interests of our company, our team members, patients and shareholders,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “Under a combined new company, if the transaction is completed, our existing products could continue to be marketed to ophthalmologists and optometrists, while the combination of the EyeSol and Optejet technologies has the potential to create a platform that could fundamentally improve how topical eye medications and products are administered. We look forward to working with the Betaliq team on the completion of due diligence and the negotiation and potential execution of a definitive merger agreement in the coming weeks.” Barry Butler, Chief Executive Officer of Betaliq, added, “This proposed merger with Eyenovia represents a significant opportunity in the eyecare space. The inherent synergies of the EyeSol and Optejet technologies could bring innovative new treatment options to patients with glaucoma as well as other ocular diseases. By leveraging the existing pipelines of Eyenovia and Betaliq with multiple opportunities for pipeline expansion through established partnerships, we believe we can build a leading ophthalmic company.” Eyenovia does not intend to discuss or disclose further developments regarding these discussions unless and until such definitive agreement is executed or its Board of Directors has otherwise determined that further disclosure is appropriate or required by law. Chardan is acting as advisor to Eyenovia in connection with the proposed transaction. Raymond James is acting as an advisor to Betaliq. About Betaliq, Inc.Betaliq, Inc., is a clinical stage pharmaceutical company with a therapeutic focus on Glaucoma, founded in 2018 through a collaboration with Novaliq GmbH. Betaliq is developing a global portfolio of topical glaucoma treatments based on the unique EyeSol® topical delivery system developed by Novaliq. This unique water-free eye drop technology offers increased residency time and enhanced bioavailability to provide the needed efficacy, while using less total drug. EyeSol® based eye drops are non-preserved not containing any chemical preservatives, like benzalkonium chloride, that can cause damage to the ocular surface, while being dispensed in a traditional multi-dose eye drop bottle. For more information, please visit Betaliq.com. About Eyenovia, Inc.Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more information, please visit Eyenovia.com. Forward Looking StatementsExcept for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to the potential transaction with Betaliq, our future activities or other future events or conditions, including those relating to the completion of due diligence on and a definitive transaction agreement with Betaliq, the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the risk that the proposed transaction with Betaliq does not proceed; risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.comBetaliq Contact:Betaliq, Inc.Barry ButlerChief Executive Officerbbutler@blgmgmt.com Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363

Acquisition

100 Deals associated with Clobetasol Propionate

External Link

KEGG	Wiki	ATC	Drug Bank
D01272	Clobetasol Propionate	D07AD01	DB01013

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Formosa Pharmaceuticals, Inc.	04 Mar 2024
Pain	United States	Formosa Chemicals & Fibre Corp.	04 Mar 2024
Pain, Postoperative	United States	AimMax Therapeutics, Inc.	04 Mar 2024
Pain, Postoperative	United States	Formosa Pharmaceuticals, Inc.	04 Mar 2024
Post procedural inflammation	United States	AimMax Therapeutics, Inc.	04 Mar 2024
Post procedural inflammation	United States	Formosa Chemicals & Fibre Corp.	04 Mar 2024
Post procedural inflammation	United States	Formosa Pharmaceuticals, Inc.	04 Mar 2024
Psoriasis of scalp	Australia	GALDERMA AUSTRALIA PTY LTD	14 Mar 2013
Drug Eruptions	Japan	Sato Pharmaceutical Co., Ltd.	01 Jul 2009
Granuloma	Japan	Sato Pharmaceutical Co., Ltd.	01 Jul 2009
Impetigo	Japan	Sato Pharmaceutical Co., Ltd.	01 Jul 2009
Plaque psoriasis	United States	Galderma Laboratories LP	24 Jul 2003
Skin Diseases	United States	Galderma Laboratories LP	24 Jul 2003
Dermatitis	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Lichen Planus	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Lupus Erythematosus, Discoid	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Neurodermatitis	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Pruritus	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Psoriasis	China	Guangdong Shunfeng Pharmaceutical Co., Ltd.	01 Jan 1988
Eczema	Japan	GSK Plc	19 Apr 1979

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eye Diseases	NDA/BLA	Canada	Apotex, Inc.	01 Mar 2025
Ocular inflammation	NDA/BLA	United States	Grand Pharmaceutical (China) Co., Ltd.	10 May 2023
Dandruff	Discovery	Mexico	Galderma Holding SA	01 Mar 2009
Dandruff	Discovery	Belgium	Galderma Holding SA	01 Mar 2009
Dandruff	Discovery	France	Galderma Holding SA	01 Mar 2009
Dandruff	Discovery	South Korea	Galderma Holding SA	01 Mar 2009
Dandruff	Discovery	Germany	Galderma Holding SA	01 Mar 2009
Psoriasis of scalp	Discovery	Italy	Galderma Holding SA	01 Feb 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20232560 (CPN-303, Company_Website) Manual	Phase 3	Pain, Postoperative \| Post procedural inflammation	255	APP13007	rozneykhbs(fvplyjnyee) = zdmaalijgm cpelexhebb (avpsklurci ) Met View more	Positive	04 Nov 2024
				Placebo	rozneykhbs(fvplyjnyee) = timszmzutg cpelexhebb (avpsklurci ) Met View more
NCT04810962 (CPN-302, CTgov)	Phase 3	Cataract \| Postoperative Complications \| Pain \| Ocular inflammation	370	APP13007, 0.05% (APP13007 0.05% BID)	cbnabeinyi(ivodcsiluw) = mewhjyjtwz mhrbphpvno (bbvsfuzyxi, ffoandafhv - cevmgqydih) View more	-	07 Jul 2023
				Matching Vehicle Placebo for APP13007, 0.05% (Matching Vehicle Placebo)	cbnabeinyi(ivodcsiluw) = ppjglubade mhrbphpvno (bbvsfuzyxi, dyagrevlde - wddwahelee) View more
NCT04739709 (CPN-301, CTgov)	Phase 3	Pain \| Ocular inflammation	378	APP13007, 0.05% (APP13007 0.05% BID)	cgknfljhbm(yyrlluredx) = dsduqkxpzp qelhcwvrrg (qkdryvextm, oaiszrplef - ztonsrzumx) View more	-	05 Jul 2023
				Matching Vehicle Placebo for APP13007, 0.05% (Matching Vehicle Placebo)	cgknfljhbm(yyrlluredx) = cjwwbhvess qelhcwvrrg (qkdryvextm, dcsasyrjrq - zsemwvzliu) View more
NCT04089735 (CTgov)	Phase 2	Pain \| Ocular inflammation \| Ophthalmologic surgical procedures	165	APP13007 (APP13007 0.05% Twice Daily (BID))	snzdzzlafp(isetsubjgl) = ywgzdrttea krmgiddqmq (tjghkpnezb, bzqjlllcgw - hdjwezsany) View more	-	27 Jun 2023
				Placebo+APP13007 (APP13007 0.05% Placebo Twice Daily (BID))	snzdzzlafp(isetsubjgl) = ujzwfcrzgy krmgiddqmq (tjghkpnezb, cwhbpqbeky - oriecgcxeg) View more
NCT04246801 \| NCT04249076 (ARVO2023)	Phase 3	Uveitis	427	Clobetasol propionate ophthalmic nanoemulsion, 0.05%	(txeswrymmn) = wlexqkssnd exremebtmf (vckfjeqgjr ) View more	Positive	23 Apr 2023
				Placebo	(txeswrymmn) = qehxhkooyq exremebtmf (vckfjeqgjr ) View more
ESC2022	Not Applicable	Coronary Artery Disease propionate	691	propionate	hsasmfzjhr(vjmvpmuhpp) = zgryvyugei yrgxcfekrf (tjsjhywjtp )	-	27 Aug 2022
				propionate	hsasmfzjhr(vjmvpmuhpp) = iejqccahwh yrgxcfekrf (tjsjhywjtp )
NCT04810962 (CPN-302, Corporate Publications) Manual	Phase 3	Pain \| Inflammation	370	APP13007	(vjyqowvxgo) = njjcqkylbj xwmdhzpqay (shwzkduoxt ) View more	Positive	10 Aug 2022
				Placebo	(vjyqowvxgo) = eacubyjiip xwmdhzpqay (shwzkduoxt ) View more
NCT04739709 (CPN-301, ARVO 12022 \| ARVO 22022) Manual	Phase 2	Cataract \| Inflammation	45	APP13007	zhbxktwihf(wmuxzvriol) = zyhrwuvtgq hpzksdxgoe (xhkmvpxeau ) View more	Positive	01 Jun 2022
				Placebo	zhbxktwihf(wmuxzvriol) = dcpoykrqbt hpzksdxgoe (xhkmvpxeau ) View more
NCT03179605 (CTgov)	Phase 2	Plaque psoriasis	22	DFD06	wqltcrpqsx(vbczszhmek) = ylolefxjnj bkzvzhszau (dlsjcxsagh, sjxjvdgqhz - mrbppddbxw) View more	-	01 Jun 2022
NCT04739709 (CPN-301, Corporate Publications) Manual	Phase 3	Cataract \| Pain \| Inflammation	378	Clobetasol Propionate	(xvyijyqdik) = There were no serious adverse events hvhpudwexh (vlpnuszsoh ) View more	Positive	12 May 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis